Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

15.04 2.59

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.71

Max

15.27

Belangrijke statistieken
By Trading Economics
Inkomsten	-4.3M -18M
EPS	-0.19
Werknemers	37
EBITDA	-5.3M -17M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+114.53% upside

Dividenden
By Acuity
Volgende Winsten	3 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	32M 1.2B
Vorige openingsprijs	12.45
Vorige sluitingsprijs	15.04

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 aug 2026, 23:56 UTC

Zions Bancorporation shares are higher in after-market hours, continuing gains amid broader market dynamics influenced by recent U.S. Consumer Price Index data.

12 aug 2026, 23:56 UTC

News

Allegro Microsystems shares rose in after-market trading following Benchmark's initiation of coverage with a Buy rating. The stock closed at $42.52.

12 aug 2026, 23:56 UTC

JinkoSolar shares are higher in after-market trading, reflecting a modest uptick since Wednesday's close amid U.S. Consumer Price Index data release.

12 aug 2026, 23:56 UTC

Yum Brands Inc. shares are higher in after-market trading, reflecting routine performance amid broader market dynamics following the release of U.S. Consumer Price Index data.

12 aug 2026, 23:56 UTC

Griffon Corp shares are higher in after-market hours, supported by U.S. Consumer Price Index data easing concerns over Federal Reserve interest rate hikes.

12 aug 2026, 23:56 UTC

Social Media

News

STAAR Surgical shares are lower in after-market hours following an EPS miss, despite reporting second-quarter net sales of $93.5 million, a 111% increase.

12 aug 2026, 23:56 UTC

MasTec Inc shares are higher in after-market hours, recovering from an earlier dip. The movement aligns with broader market dynamics following U.S. CPI data.

12 aug 2026, 23:56 UTC

Molina Healthcare Inc shares are higher in after-market hours, following the release of U.S. Consumer Price Index data that met expectations.

12 aug 2026, 23:56 UTC

Ionis Pharmaceuticals Inc. shares are lower in after-market trading, despite remaining above their 20-day moving average and within the upper range for the month.

12 aug 2026, 23:56 UTC

ETF Constituents

Vanguard FTSE Emerging Markets ETF shows modest after-market gains, supported by Taiwan Semiconductor and Pinduoduo. The ETF is near its one-month range's upper end.

12 aug 2026, 23:56 UTC

Ares Capital Corp shares are lower in after-market hours, continuing a three-session decline amid market volatility following U.S. Consumer Price Index data release.

12 aug 2026, 23:56 UTC

DaVita Inc shares are lower in after-market trading following a session peak. The stock remains under pressure, trading below its 20-day moving average.

12 aug 2026, 23:56 UTC

ETF Constituents

Correlated Moves

VanEck Gold Miners ETF declines in after-market trading, impacted by top holdings including Pan American Silver's drop and slight decreases in silver prices.

12 aug 2026, 23:56 UTC

Chevron Corp shares gained during after-market hours following the release of U.S. Consumer Price Index data, which eased concerns about Federal Reserve interest rate hikes.

12 aug 2026, 23:56 UTC

Social Media

Snowflake Inc. shares advanced in after-market trading, buoyed by U.S. CPI data and positive sentiment in tech sector discussions.

12 aug 2026, 23:56 UTC

Bristol-Myers Squibb Co shares rose in after-market trading following U.S. Consumer Price Index data, easing concerns about aggressive Federal Reserve interest rate hikes.

12 aug 2026, 23:56 UTC

Gogo Inc. shares are higher in after-market trading, following the release of U.S. Consumer Price Index data that met expectations and eased rate hike concerns.

12 aug 2026, 23:56 UTC

Comcast shares declined in after-market trading, following the release of U.S. Consumer Price Index data. The stock remains above its 20-day moving average.

12 aug 2026, 23:56 UTC

elf Beauty Inc. shares are lower in after-market trading, continuing a four-session decline. The stock remains above its 20-day moving average.

12 aug 2026, 23:54 UTC

Ambarella Inc. shares remained roughly flat in after-market hours, with no specific news identified. The stock is positioned above its 20-day moving average.

12 aug 2026, 23:52 UTC

UK House Price Balance Shows Slight Improvement at -0.3%, Indicating Ongoing Market Challenges Despite Optimism for Future Stabilization

12 aug 2026, 23:52 UTC

RBA Holds Cash Rate at 4.35% Amid Inflation Concerns; Assistant Governor Kent's Upcoming Speech Sparks Market Speculation

12 aug 2026, 23:52 UTC

Canada's housing starts data set for release on August 18, following June's decline and amid government initiatives to boost affordable home construction.

12 aug 2026, 23:52 UTC

Australia's Consumer Confidence Report Set for August 18 Amidst Cautious Market Sentiment and Economic Volatility.

12 aug 2026, 23:52 UTC

Australia's Consumer Confidence Index release on August 18, 2026, faces cautious market expectations amid mixed economic signals and ongoing geopolitical tensions.

12 aug 2026, 23:52 UTC

Brazil's Industrial Entrepreneur Confidence Index Expected to Remain Low Amid Economic Uncertainty, Anticipating Continued Pessimism Ahead of August 13 Release.

12 aug 2026, 23:52 UTC

Australia's Investment Lending Data Release on August 14 Expected to Impact Housing Market Insights Amid Cautious Sentiment.

12 aug 2026, 23:52 UTC

Japan's Upcoming Export Data Release on August 19, 2026, Expected to Reflect Trends in High-Tech Products Amid Global Economic Uncertainties.

12 aug 2026, 23:52 UTC

Japan's Upcoming Balance of Trade Data Expected to Show Continued Deficits Amid Rising Imports and Geopolitical Tensions

12 aug 2026, 23:52 UTC

JD.Com Inc. shares are lower in after-hours trading, reversing from an early gain amid broader market trends influenced by recent inflation data.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

114.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 114.53%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.